Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Suzhou Suncadia Biopharmaceuticals is the lead sponsor of 71 current clinical trials in our China register. 53 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Adebrelimab, SHR-8068 and Bevacizumab. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

Recruiting5375%
Not yet open811%
Active, closed1014%

Trials by phase

Phase 32231%
Phase 11724%
Phase 21623%
Phase 1/21318%
Phase 2/323%
Phase 411%

Clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals

71 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma NCT07478302 · ClinicalTrials.gov ↗ · Advanced Unresectable Hepatocellular Carcinoma Drug: Bevacizumab	Phase 1	Recruiting	2026-04	China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832 · ClinicalTrials.gov ↗ · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer Drugs: Adebrelimab, Paclitaxel, Toripalimab	Phase 3	Recruiting	2025-08	China
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors NCT07229638 · ClinicalTrials.gov ↗ · Solid Tumor Drug: SHR-9839	Phase 1/2	Recruiting	2026-02	China
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma NCT06618664 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma Drugs: Adebrelimab, Atezolizumab, Bevacizumab	Phase 3	Recruiting	2024-10	China
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors NCT07028268 · ClinicalTrials.gov ↗ · For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors	Phase 2	Recruiting	2025-06	China
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma NCT07393542 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Urothelial Carcinoma	Phase 3	Recruiting	2026-02	China
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors NCT07028281 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 2	Recruiting	2025-07	China
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer NCT07679360 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer Drugs: Adebrelimab, Capecitabine, Pembrolizumab	Phase 3	Recruiting	2026-09	China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors NCT06703177 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drugs: Adebrelimab, Bevacizumab, Calcium folinate	Phase 1/2	Recruiting	2025-02	China
A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis NCT06860750 · ClinicalTrials.gov ↗ · Active Non-radiographic Axial Spondyloarthritis	Phase 3	Recruiting	2025-04	China
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer NCT06859775 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer Drugs: Adebrelimab, Bevacizumab, Carboplatin	Phase 1/2	Recruiting	2025-04	China
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC NCT07183189 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Aumolertinib, SHR-A2009	Phase 3	Recruiting	2025-10	China
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors NCT06737731 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 1/2	Recruiting	2025-01	China
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer NCT07418749 · ClinicalTrials.gov ↗ · Recurrent Cervical Cancer, Metastatic Cervical Cancer	Phase 3	Recruiting	2026-03	China
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor NCT07275242 · ClinicalTrials.gov ↗ · Solid Tumor Drug: Trastuzumab Rezetecan	Phase 1	Recruiting	2025-12	China
A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors NCT07068932 · ClinicalTrials.gov ↗ · Malignant Tumors of Adults	Phase 1	Recruiting	2025-07	China
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors NCT06643754 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	2024-12	China
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors NCT07123129 · ClinicalTrials.gov ↗ · Advanced Malignancy	Phase 1	Recruiting	2025-08	China
A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects NCT07414602 · ClinicalTrials.gov ↗ · Dermatitis	Phase 1	Recruiting	2026-03	China
A Clinical Study of SHR-5421 in Patients With Multiple Myeloma NCT07652281 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Recruiting	2026-07	China
A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors NCT07676903 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	2026-08	China
A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer NCT07676162 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 3	Recruiting	2026-08	China
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT07170995 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 3	Recruiting	2025-10	China
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer NCT07735377 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 1	Recruiting	2026-08	China
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drug: SHR-A1904	Phase 2	Recruiting	2026-03	China
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer NCT05300269 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	2022-07	China
A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07751341 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma Drug: SHR-9839	Phase 2	Recruiting	2026-09	China
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer NCT07110571 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer Drugs: Adebrelimab, SHR-8068, SHR-A1904	Phase 2	Recruiting	2025-08	China
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer NCT07454720 · ClinicalTrials.gov ↗ · Locally Advanced Resectable Rectal Cancer Drug: Adebrelimab	Phase 2/3	Recruiting	2026-03	China
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	2025-08	China
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors NCT07229612 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 1/2	Recruiting	2025-12	China
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC NCT07726992 · ClinicalTrials.gov ↗ · Papillary-Only Non-muscle-invasive Bladder Cancer Drug: SHR-1501	Phase 3	Recruiting	2026-08	China
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC NCT06844474 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Recruiting	2025-03	China
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer NCT05671822 · ClinicalTrials.gov ↗ · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	2023-03	China
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) NCT06879145 · ClinicalTrials.gov ↗ · Muscular Invasive Bladder Cancer (MIBC)	Phase 2/3	Recruiting	2025-04	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Adebrelimab, Bevacizumab, Carboplatin	Phase 1/2	Recruiting	2025-03	China
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC NCT07424287 · ClinicalTrials.gov ↗ · NMIBC Drugs: Epirubicin Hydrochloride, Gemcitabine Hydrochloride, Mitomycin	Phase 3	Recruiting	2026-07	China
A Trial of SHR-4849 in Advanced Solid Tumors NCT06443489 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: SHR-4849	Phase 1	Recruiting	2024-06	China
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Doxorubicin, Paclitaxel, SHR-A1921	Phase 3	Recruiting	2024-05	China
Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom NCT07239596 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma Drugs: SHR-4610, SHR-8068	Phase 1/2	Recruiting	2026-01	China
A Study of SHR-4375 in Subjects With Solid Tumors NCT06764628 · ClinicalTrials.gov ↗ · Solid Tumors Drug: SHR-4375	Phase 1/2	Recruiting	2025-01	China
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma NCT06484777 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Recruiting	2024-08	China
A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma NCT07661537 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma	Phase 1	Recruiting	2026-07	China
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer NCT07489716 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: SHR-1826	Phase 2	Recruiting	2026-04	China
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors NCT06618651 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2024-11	China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer NCT07059221 · ClinicalTrials.gov ↗ · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Drugs: Adebrelimab, Cetuximab, Ivonescimab	Phase 1/2	Recruiting	2025-07	China
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031 · ClinicalTrials.gov ↗ · HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer Drugs: Adebrelimab, SHR-8068, Trastuzumab Rezetecan	Phase 2	Recruiting	2025-02	China
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors NCT07298772 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drug: SHR-4375	Phase 1/2	Recruiting	2026-01	China
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors NCT06094556 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: SHR-1826	Phase 1	Recruiting	2023-12	China
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC) NCT07229625 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer Drugs: Adebrelimab, Cisplatin, Durvalumab	Phase 3	Recruiting	2026-01	China
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma NCT06929624 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma Drugs: Gemcitabine Hydrochloride, Oxaliplatin, Rituximab	Phase 3	Recruiting	2025-04	China
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors NCT06907628 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2025-04	China
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC NCT06754930 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC) Drugs: Adebrelimab, Ametinib Mesylate, Carboplatin	Phase 1/2	Recruiting	2025-02	China
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer NCT07704645 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer Drugs: Adebrelimab, HRS-7058, SHR-1826	Phase 2	Not yet open	2026-08	China
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics NCT07830199 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Not yet open	2026-09	China
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis NCT06779097 · ClinicalTrials.gov ↗ · Moderate to Severe Plaque Psoriasis Drug: Vunakizumab	Phase 4	Not yet open	2025-02	China
The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis NCT06833307 · ClinicalTrials.gov ↗ · Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis Drug: SHR-1314	Phase 3	Not yet open	2025-02	China
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients NCT06592625 · ClinicalTrials.gov ↗ · Untreated Early-stage or Locally Advanced Breast Cancer Drugs: Adebrelimab, Trastuzumab Rezetecan	Phase 2	Not yet open	2024-09	China
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma NCT07691762 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Adebrelimab, Bevacizumab, SHR-8068	Phase 3	Not yet open	2026-07	China
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma NCT07682272 · ClinicalTrials.gov ↗ · Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk	Phase 2	Not yet open	2026-07	China
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer NCT07779538 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Bevacizumab, Trastuzumab	Phase 3	Not yet open	2026-09	China
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors NCT05765032 · Advanced Solid Tumor Drug: SHR-A1921	Phase 1/2	Active, closed	2022-12	China
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer NCT06247956 · ClinicalTrials.gov ↗ · Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Drugs: Adebrelimab, Capecitabine, Cisplatin	Phase 2	Active, closed	2024-03	China
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors NCT05114759 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: SHR-A2009	Phase 1	Active, closed	2022-01	China
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan NCT06199973 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer Drug: Trastuzumab Rezetecan	Phase 3	Active, closed	2024-03	China
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC NCT06671379 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: SHR-A2009	Phase 3	Active, closed	2024-11	China
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer NCT07071714 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Adebrelimab, Bevacizumab, SHR-8068	Phase 2	Active, closed	2025-07	China
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer NCT07009457 · ClinicalTrials.gov ↗ · Widespread Small Cell Lung Cancer Drugs: Adebrelimab, Carboplatin, Etoposide	Phase 1	Active, closed	2025-06	China
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer NCT06465563 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: Adebrelimab, Bevacizumab, Cisplatin	Phase 2	Active, closed	2024-07	China
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer NCT04950322 · ClinicalTrials.gov ↗ · Gastric or Gastroesophageal Junction Cancer	Phase 3	Active, closed	2021-12	China
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis NCT06640257 · ClinicalTrials.gov ↗ · Psoriatic Arthritis Drug: SHR-1314	Phase 3	Active, closed	2024-11	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Suzhou Suncadia Biopharmaceuticals trials

43 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 3 more in the trial list above.

Conditions in Suzhou Suncadia Biopharmaceuticals trials

55 conditions

Advanced Solid Tumors7 Solid Tumor4Malignant Solid Tumors3Ovarian Cancer3 Advanced Solid Tumor2 Advanced Colorectal Cancer2 Non-small Cell Lung Cancer2 Multiple Myeloma2 Biliary Tract Cancer2Advanced Unresectable Hepatocellular Carcinoma1Resectable Non-small Cell Lung Cancer1PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1Advanced Hepatocellular Carcinoma1Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma1For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors1Locally Advanced or Metastatic Urothelial Carcinoma1Triple Negative Breast Cancer1Active Non-radiographic Axial Spondyloarthritis1Recurrent or Metastatic Cervical Cancer1Recurrent Cervical Cancer1Metastatic Cervical Cancer1Malignant Tumors of Adults1Colorectal Cancer1Advanced Malignancy1

By trial register

Register	Trials	Recruiting
Clinical trials in China	71	53

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumors

Sponsor	Trials
Sichuan Kelun-Biotech Biopharmaceutical	9
Jiangsu HengRui Medicine	7
Shanghai Hengrui Pharmaceutical	6
Bristol-Myers Squibb	5
MediLink Therapeutics (Suzhou)	5
Hangzhou Zhongmei Huadong Pharmaceutical	5
Hansoh BioMedical R&D Company	4
Bayer	3
Vividion Therapeutics	3
Multitude Therapeutics	3

Sponsors with the most current trials registered for this condition.

Questions about Suzhou Suncadia Biopharmaceuticals trials

How many clinical trials does Suzhou Suncadia Biopharmaceuticals sponsor?

Suzhou Suncadia Biopharmaceuticals is the lead sponsor of 71 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Suzhou Suncadia Biopharmaceuticals trials recruiting?

Yes. 53 of its 71 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Suzhou Suncadia Biopharmaceuticals testing?

Its current trials name 43 drugs and biologicals as interventions. The most frequent are Adebrelimab (19), SHR-8068 (13), Bevacizumab (9), Trastuzumab Rezetecan (9) and SHR-1826 (5). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Suzhou Suncadia Biopharmaceuticals clinical trials